Roche Partners with Broad Clinical Labs on SBX Sequencing Technology for Neonatal Genetic Diagnosis
BURLINGTON, Mass., May 23, 2025 (Broad Clinical Labs) — Roche announces strategic collaboration with Broad Clinical Labs to develop groundbreaking applications using SBX sequencing technology, targeting rapid genetic diagnosis for critically ill newborns in neonatal intensive care units.
Candel Therapeutics’ CAN-2409 Shows 30% Reduction in Prostate Cancer Recurrence – Phase 3 Results at ASCO 2025
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics reveals breakthrough Phase 3 results for CAN-2409 prostate cancer treatment, demonstrating significant reduction in disease recurrence and pathological complete response rates ahead of ASCO 2025 presentation.
Governor Abbott Announces NTxBio Facility In Plano
PLANO, Texas., May 15 /ntxbio.com/ — Governor Abbott announces NTxBio’s major expansion into Plano with a $31 million biomanufacturing facility creating over 170 jobs, supported by Texas Enterprise Fund investment to strengthen the state’s life sciences sector.
Oligo Factory Launches Low-Scale Oligo Synthesis Capability to Broaden Support for Therapeutic and Diagnostic Researchers and Developers
HOLLISTON, Mass., May 19, 2025 /Oligo Factory Communications/ — Oligo Factory launches new low-scale oligo synthesis capability, enabling researchers to order custom DNA and RNA oligonucleotides at volumes as low as 50 nmol while maintaining high quality and service standards. The company also introduces its FactorTx™ portfolio to support therapeutic development from discovery through clinical phases.
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24 /PRNewswire/ — Sermonix Pharmaceuticals and Regor Therapeutics Group have entered a strategic collaboration. The partnership will utilize Regor’s rCARD™ platform to identify novel targets and therapeutics for metastatic breast cancer, aiming for treatments that balance efficacy with tolerability and quality of life.
Circular Genomics Strengthens Scientific Advisory Board with Addition of Alzheimer’s Disease Expert
Mar. 19, 2025 /Circular Genomics Communications/ — Circular Genomics has appointed Phyllis Ferrell, MBA, DrPH, a recognized expert in Alzheimer’s disease (AD), dementia care, and global health, to its Scientific Advisory Board (SAB). Her expertise will support the company’s development of circular RNA (circRNA) biomarkers for neurological and psychiatric disorders, particularly AD.
Circular Genomics Joins Lilly Gateway Labs in San Diego to Develop Its Best-In-Class Circular RNA Platform for the Diagnosis and Prognosis of Alzheimer’s Disease
Mar. 17, 2025 /Circular Genomics Communications/ — Circular Genomics announced it is moving its headquarters to Lilly Gateway Labs in San Diego. The move aims to accelerate the development of its circular RNA (circRNA) biomarker platform for Alzheimer’s disease diagnostic and prognostic blood tests through collaboration and access to resources.
Count Me In Launches tRCC Patient Research Project
Mar. 11, 2025 /Count Me In Communications/ — Count Me In has launched a new patient-partnered research project focused on translocation renal cell carcinoma (tRCC), a rare kidney cancer. The tRCC Project enables patients to securely share their unique health data and experiences online to accelerate research and the development of new treatments.
AGC Biologics Honored at CDMO Leadership Awards for Excellence in Quality, Biologics and Cell and Gene Therapies
SEATTLE, Mar. 10, 2025 /PRNewswire/ — AGC Biologics announced it has won two 2025 CDMO Leadership Awards, recognizing its global excellence in both Biologics and Cell & Gene therapy services based on surveys of industry leaders.
Stellaromics Secures Significant Funding to Advance 3D Spatial Biology
BOSTON, Feb. 11, 2025 /PRNewswire/ — Stellaromics announced an $80M Series B funding round led by Catalyst4. The investment will support the debut of Pyxa, an innovative platform built on STARmap and RIBOmap technologies that enables detailed 3D analysis of thick tissue samples.
